You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevomilnacipran
Accession NumberDB08918
TypeSmall Molecule
GroupsApproved
DescriptionLevomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor. Chemically, levomilnacipran is the 1S,2R-enantiomer of milnacipran. FDA approved on July 25, 2013.
Structure
Thumb
Synonyms
(1S,2R)-milnacipran
External Identifiers
  • F 2695
  • F-2695
  • F2695
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fetzimacapsule (extended release)20 mgoralActavis Specialty Pharmaceuticals Co2015-11-19Not applicableCanada
FetzimakitoralForest Laboratories, Inc.2013-07-25Not applicableUs
Fetzimacapsule, extended release80 mg/1oralForest Laboratories, Inc.2013-07-25Not applicableUs
Fetzimacapsule (extended release)40 mgoralActavis Specialty Pharmaceuticals Co2015-11-19Not applicableCanada
Fetzimacapsule, extended release120 mg/1oralForest Laboratories, Inc.2013-07-25Not applicableUs
Fetzimacapsule (extended release)80 mgoralActavis Specialty Pharmaceuticals CoNot applicableNot applicableCanada
Fetzimacapsule, extended release40 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Fetzimacapsule, extended release20 mg/1oralForest Laboratories, Inc.2013-07-25Not applicableUs
Fetzimacapsule (extended release)120 mgoralActavis Specialty Pharmaceuticals CoNot applicableNot applicableCanada
Fetzimacapsule, extended release40 mg/1oralForest Laboratories, Inc.2013-07-25Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Levomilnacipran hydrochloride
175131-60-9
Thumb
  • InChI Key: XNCDYJFPRPDERF-NQQJLSKUSA-N
  • Monoisotopic Mass: 282.149891075
  • Average Mass: 282.809
DBSALT000107
Categories
UNIIUGM0326TXX
CAS number96847-54-0
WeightAverage: 246.348
Monoisotopic: 246.173213336
Chemical FormulaC15H22N2O
InChI KeyGJJFMKBJSRMPLA-DZGCQCFKSA-N
InChI
InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1
IUPAC Name
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
SMILES
CCN(CC)C(=O)[C@]1(C[[email protected]]1CN)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetamides
Direct ParentPhenylacetamides
Alternative Parents
Substituents
  • Phenylacetamide
  • Aralkylamine
  • Cyclopropanecarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationLevomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD).
PharmacodynamicsLevomilnacipran binds with high affinity to human serotonin (5-HT) and norepinephrine (NE) transporters (Ki = 11 and 91 nM, respectively). It potently inhibits 5-HT and NE reuptake (IC50 = 16 - 19 and 11 nM, respectively). Levomilnacipran does not bind to any other receptors, ion channels, or transporters, including serotonergic (5HT1-7), α- and β adrenergic, muscarinic, or histaminergic receptors and Ca2+, Na+, K+ or Cl- channels to a significant degree. Levomilnacipran did not inhibit monoamine oxidase (MAO). Furthermore, levomilnacipran does not prolong the QTc interval to a clinically relevant extent.
Mechanism of actionThe exact mechanism of the antidepressant action of levomilnacipran is unknown but is thought to be related to the potentiation of serotonin and norephinephrine in the central nervous system through inhibition of reuptake at serotonin and norepinephrine transporters.
Related Articles
AbsorptionThe relative bioavailability after administration of the extended-release capsule was 92% when compared to oral solution. Food does not affect the concentration of levomilnacipran. After daily dosing of levomilnacipran (extended-release capsule) the mean Cmax is 341 ng/mL, and the mean steady-state AUC value is 5196 ng·h/mL. The Tmax is 6 - 8 hours after oral administration. Interconversion of stereoisomers does not occur in humans.
Volume of distribution
  • 387 – 473 L [apparent volume of distribution]
Protein binding22% bound to human plasma protein over concentration range of 10 to 1000 ng/mL.
Metabolism

Hepatic. Levomilnacipran undergoes desethylation to form desethyl levomilnacipran and hydroxylation to form p-hydroxy-levomilnacipran. Desethylation is facilitated primarily by CYP3A4 and by CYP2C8, 2C19, 2D6, and 2J2 to a lesser extent. Both metabolites undergo further conjugation with glucuronide to form conjugates.

Route of eliminationLevomilnacipran and its metabolites are eliminated primarily by renal excretion. 58% of the dose is excreted in urine as unchanged levomilnacipran. N-desethyl levomilnacipran is the major metabolite excreted in the urine and accounted for approximately 18% of the dose. Other identifiable metabolites excreted in the urine are levomilnacipran glucuronide (4%), desethyl-levomilnacipran glucuronide (3%), p-hydroxy levomilnacipran glucuronide (1%), and p-hydroxylevomilnacipran (1%). The metabolites are inactive.
Half life12 hours
Clearance
  • 21 – 29 L/h [mean apparent total clearance]
ToxicityThe most common adverse reactions are nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9889
Caco-2 permeable+0.5914
P-glycoprotein substrateSubstrate0.5928
P-glycoprotein inhibitor INon-inhibitor0.902
P-glycoprotein inhibitor IINon-inhibitor0.8787
Renal organic cation transporterNon-inhibitor0.8119
CYP450 2C9 substrateNon-substrate0.8494
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6514
CYP450 1A2 substrateNon-inhibitor0.6383
CYP450 2C9 inhibitorNon-inhibitor0.7697
CYP450 2D6 inhibitorNon-inhibitor0.7718
CYP450 2C19 inhibitorNon-inhibitor0.8587
CYP450 3A4 inhibitorNon-inhibitor0.6327
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7004
Ames testNon AMES toxic0.8013
CarcinogenicityNon-carcinogens0.5456
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.6162 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.993
hERG inhibition (predictor II)Non-inhibitor0.6823
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsule (extended release)oral120 mg
Capsule (extended release)oral20 mg
Capsule (extended release)oral40 mg
Capsule (extended release)oral80 mg
Capsule, extended releaseoral120 mg/1
Capsule, extended releaseoral20 mg/1
Capsule, extended releaseoral40 mg/1
Capsule, extended releaseoral80 mg/1
Kitoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8481598 No2011-03-022031-03-02Us
US8865937 No2012-05-232032-05-23Us
USRE43879 No2003-06-032023-06-03Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP1.42ChemAxon
pKa (Strongest Basic)9.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.81 m3·mol-1ChemAxon
Polarizability28.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 28:16.04.16
PDB EntriesNot Available
FDA labelDownload (530 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineLevomilnacipran may decrease the antihypertensive activities of 4-Methoxyamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levomilnacipran.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Levomilnacipran.
AbirateroneThe serum concentration of Levomilnacipran can be increased when it is combined with Abiraterone.
AcarboseLevomilnacipran may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.
AcenocoumarolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Levomilnacipran.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levomilnacipran.
AcetaminophenThe serum concentration of Levomilnacipran can be increased when it is combined with Acetaminophen.
AcetophenazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Acetophenazine.
Acetylsalicylic acidLevomilnacipran may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Levomilnacipran.
AfatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Afatinib.
AgmatineLevomilnacipran may decrease the antihypertensive activities of Agmatine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levomilnacipran.
AlbendazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Albendazole.
AlbiglutideLevomilnacipran may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Levomilnacipran can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levomilnacipran.
AlfentanilAlfentanil may increase the serotonergic activities of Levomilnacipran.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Levomilnacipran.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Levomilnacipran.
AlogliptinLevomilnacipran may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Levomilnacipran.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomilnacipran.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Levomilnacipran.
AmantadineThe serum concentration of Levomilnacipran can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Levomilnacipran can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levomilnacipran.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levomilnacipran.
AmlodipineThe serum concentration of Levomilnacipran can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levomilnacipran.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levomilnacipran.
AmoxapineLevomilnacipran may increase the serotonergic activities of Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Levomilnacipran.
AmprenavirThe serum concentration of Levomilnacipran can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Levomilnacipran can be increased when it is combined with Amsacrine.
ApomorphineLevomilnacipran may decrease the antihypertensive activities of Apomorphine.
AprepitantThe serum concentration of Levomilnacipran can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomilnacipran.
ArmodafinilThe metabolism of Levomilnacipran can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Levomilnacipran.
ArtemetherThe metabolism of Levomilnacipran can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Levomilnacipran.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levomilnacipran.
AstemizoleThe serum concentration of Levomilnacipran can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Levomilnacipran can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Levomilnacipran.
AtomoxetineThe metabolism of Levomilnacipran can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Levomilnacipran can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Levomilnacipran.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levomilnacipran.
AzithromycinThe serum concentration of Levomilnacipran can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Levomilnacipran.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Levomilnacipran.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Levomilnacipran.
BendroflumethiazideLevomilnacipran may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Levomilnacipran.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Levomilnacipran.
BenzphetamineLevomilnacipran may decrease the antihypertensive activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levomilnacipran.
BepridilThe serum concentration of Levomilnacipran can be increased when it is combined with Bepridil.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Levomilnacipran.
BetaxololThe metabolism of Levomilnacipran can be decreased when combined with Betaxolol.
BethanidineLevomilnacipran may decrease the antihypertensive activities of Bethanidine.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Levomilnacipran.
BexaroteneThe serum concentration of Levomilnacipran can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Levomilnacipran.
BifeprunoxThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Bifeprunox.
BiperidenThe serum concentration of Levomilnacipran can be increased when it is combined with Biperiden.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Levomilnacipran.
BoceprevirThe serum concentration of Levomilnacipran can be increased when it is combined with Boceprevir.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Levomilnacipran.
BortezomibThe metabolism of Levomilnacipran can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Levomilnacipran can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Levomilnacipran can be increased when it is combined with Bosutinib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Levomilnacipran.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levomilnacipran.
BrimonidineLevomilnacipran may decrease the antihypertensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levomilnacipran.
BromocriptineLevomilnacipran may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe serum concentration of Levomilnacipran can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levomilnacipran.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Levomilnacipran.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Levomilnacipran.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomilnacipran.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Levomilnacipran.
BuprenorphineBuprenorphine may increase the serotonergic activities of Levomilnacipran.
BupropionThe metabolism of Levomilnacipran can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levomilnacipran.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomilnacipran.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Levomilnacipran.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Levomilnacipran.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Levomilnacipran.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Levomilnacipran.
ButorphanolButorphanol may increase the serotonergic activities of Levomilnacipran.
CabazitaxelThe serum concentration of Levomilnacipran can be increased when it is combined with Cabazitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Levomilnacipran.
CaffeineThe serum concentration of Levomilnacipran can be increased when it is combined with Caffeine.
CanagliflozinLevomilnacipran may increase the hypoglycemic activities of Canagliflozin.
CanagliflozinThe serum concentration of Levomilnacipran can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Levomilnacipran can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Levomilnacipran can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Levomilnacipran.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levomilnacipran.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levomilnacipran.
CarfentanilCarfentanil may increase the serotonergic activities of Levomilnacipran.
CariprazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomilnacipran.
CaroxazoneCaroxazone may increase the serotonergic activities of Levomilnacipran.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Levomilnacipran.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Levomilnacipran.
CaspofunginThe serum concentration of Levomilnacipran can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Levomilnacipran can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Levomilnacipran.
CeritinibThe serum concentration of Levomilnacipran can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levomilnacipran.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levomilnacipran.
ChloramphenicolThe metabolism of Levomilnacipran can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levomilnacipran.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Levomilnacipran.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomilnacipran.
ChloroquineThe serum concentration of Levomilnacipran can be increased when it is combined with Chloroquine.
ChlorothiazideLevomilnacipran may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levomilnacipran.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levomilnacipran.
ChlorpropamideLevomilnacipran may increase the hypoglycemic activities of Chlorpropamide.
ChlorpropamideThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levomilnacipran.
ChlorthalidoneLevomilnacipran may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levomilnacipran.
CholecalciferolThe metabolism of Levomilnacipran can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Levomilnacipran can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Levomilnacipran can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Levomilnacipran can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Levomilnacipran can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Levomilnacipran can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomilnacipran.
CiprofloxacinThe serum concentration of Levomilnacipran can be increased when it is combined with Ciprofloxacin.
CitalopramLevomilnacipran may increase the serotonergic activities of Citalopram.
CitalopramThe serum concentration of Levomilnacipran can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Levomilnacipran can be increased when it is combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Levomilnacipran.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Levomilnacipran.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Levomilnacipran.
ClofazimineThe serum concentration of Levomilnacipran can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Levomilnacipran.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levomilnacipran.
ClomipramineLevomilnacipran may increase the serotonergic activities of Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levomilnacipran.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levomilnacipran.
ClonidineLevomilnacipran may decrease the antihypertensive activities of Clonidine.
ClopidogrelThe metabolism of Levomilnacipran can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomilnacipran.
ClotrimazoleThe metabolism of Levomilnacipran can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levomilnacipran.
CobicistatThe serum concentration of Levomilnacipran can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levomilnacipran.
CodeineCodeine may increase the serotonergic activities of Levomilnacipran.
ColchicineThe serum concentration of Levomilnacipran can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Levomilnacipran can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Levomilnacipran can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Levomilnacipran can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levomilnacipran.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomilnacipran.
CyclophosphamideThe serum concentration of Levomilnacipran can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.
CyproheptadineThe therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Cyproheptadine.
DabrafenibThe serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Levomilnacipran can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Levomilnacipran can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.
DapagliflozinLevomilnacipran may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomilnacipran.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Levomilnacipran.
DapoxetineLevomilnacipran may increase the serotonergic activities of Dapoxetine.
DarifenacinThe metabolism of Levomilnacipran can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Levomilnacipran can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Levomilnacipran can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Levomilnacipran can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Levomilnacipran can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Levomilnacipran.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomilnacipran.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Levomilnacipran.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levomilnacipran.
DesmopressinThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Levomilnacipran.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Levomilnacipran.
DexamethasoneThe serum concentration of Levomilnacipran can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levomilnacipran.
DexmedetomidineLevomilnacipran may decrease the antihypertensive activities of Dexmedetomidine.
DextromethorphanLevomilnacipran may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe serum concentration of Levomilnacipran can be increased when it is combined with Dextromethorphan.
DextromoramideDextromoramide may increase the serotonergic activities of Levomilnacipran.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Levomilnacipran.
DezocineDezocine may increase the serotonergic activities of Levomilnacipran.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levomilnacipran.
DiclofenacThe serum concentration of Levomilnacipran can be increased when it is combined with Diclofenac.
DicoumarolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Levomilnacipran.
DigoxinThe serum concentration of Levomilnacipran can be decreased when it is combined with Digoxin.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Levomilnacipran.
DihydroergotamineThe metabolism of Levomilnacipran can be decreased when combined with Dihydroergotamine.
DihydroergotamineLevomilnacipran may decrease the antihypertensive activities of Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Levomilnacipran.
DihydromorphineDihydromorphine may increase the serotonergic activities of Levomilnacipran.
DiltiazemThe metabolism of Levomilnacipran can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levomilnacipran.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levomilnacipran.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Levomilnacipran.
DipivefrinLevomilnacipran may decrease the antihypertensive activities of Dipivefrin.
DipyridamoleThe serum concentration of Levomilnacipran can be increased when it is combined with Dipyridamole.
DisopyramideLevomilnacipran may increase the hypoglycemic activities of Disopyramide.
DolasetronDolasetron may increase the serotonergic activities of Levomilnacipran.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Levomilnacipran.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Levomilnacipran.
DoxazosinThe serum concentration of Levomilnacipran can be increased when it is combined with Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.
DoxorubicinThe serum concentration of Levomilnacipran can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Levomilnacipran can be decreased when combined with Doxycycline.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Levomilnacipran.
DPDPEDPDPE may increase the serotonergic activities of Levomilnacipran.
DronabinolThe serum concentration of Levomilnacipran can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Levomilnacipran can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Levomilnacipran.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Levomilnacipran.
DroxidopaLevomilnacipran may decrease the antihypertensive activities of Droxidopa.
DulaglutideLevomilnacipran may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Levomilnacipran can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Levomilnacipran.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Levomilnacipran.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levomilnacipran.
ElbasvirThe serum concentration of Levomilnacipran can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Levomilnacipran.
EliglustatThe metabolism of Levomilnacipran can be decreased when combined with Eliglustat.
EmpagliflozinLevomilnacipran may increase the hypoglycemic activities of Empagliflozin.
EnalaprilThe serum concentration of Levomilnacipran can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levomilnacipran.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Levomilnacipran.
EnzalutamideThe serum concentration of Levomilnacipran can be increased when it is combined with Enzalutamide.
EphedraLevomilnacipran may decrease the antihypertensive activities of Ephedra.
EpinephrineLevomilnacipran may decrease the antihypertensive activities of Epinephrine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.
ErgonovineThe serum concentration of Levomilnacipran can be increased when it is combined with Ergonovine.
ErgonovineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ergonovine.
ErgotamineThe serum concentration of Levomilnacipran can be increased when it is combined with Ergotamine.
ErgotamineLevomilnacipran may decrease the antihypertensive activities of Ergotamine.
ErythromycinThe metabolism of Levomilnacipran can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the serotonergic activities of Levomilnacipran.
Eslicarbazepine acetateThe serum concentration of Levomilnacipran can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Levomilnacipran.
EsomeprazoleThe metabolism of Levomilnacipran can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levomilnacipran.
EstramustineThe serum concentration of Levomilnacipran can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Levomilnacipran can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomilnacipran.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Levomilnacipran.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomilnacipran.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levomilnacipran.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levomilnacipran.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levomilnacipran.
EthylmorphineEthylmorphine may increase the serotonergic activities of Levomilnacipran.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Levomilnacipran.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Levomilnacipran.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Levomilnacipran.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomilnacipran.
EtomidateLevomilnacipran may decrease the antihypertensive activities of Etomidate.
EtoperidoneLevomilnacipran may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Levomilnacipran can be increased when it is combined with Etoposide.
EtorphineEtorphine may increase the serotonergic activities of Levomilnacipran.
EtravirineThe serum concentration of Levomilnacipran can be decreased when it is combined with Etravirine.
ExenatideLevomilnacipran may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Levomilnacipran.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Levomilnacipran.
FelodipineThe serum concentration of Levomilnacipran can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levomilnacipran.
FenfluramineFenfluramine may increase the serotonergic activities of Levomilnacipran.
FentanylFentanyl may increase the serotonergic activities of Levomilnacipran.
FentanylThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levomilnacipran.
FidaxomicinThe serum concentration of Levomilnacipran can be increased when it is combined with Fidaxomicin.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levomilnacipran.
FluconazoleThe metabolism of Levomilnacipran can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levomilnacipran.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levomilnacipran.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levomilnacipran.
FluoxetineLevomilnacipran may increase the serotonergic activities of Fluoxetine.
FluoxetineThe serum concentration of Levomilnacipran can be increased when it is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levomilnacipran.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomilnacipran.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levomilnacipran.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levomilnacipran.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levomilnacipran.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Levomilnacipran.
FluvoxamineLevomilnacipran may increase the serotonergic activities of Fluvoxamine.
FosamprenavirThe metabolism of Levomilnacipran can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Levomilnacipran can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Levomilnacipran.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levomilnacipran.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Levomilnacipran.
FurazolidoneFurazolidone may increase the serotonergic activities of Levomilnacipran.
Fusidic AcidThe serum concentration of Levomilnacipran can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomilnacipran.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Levomilnacipran.
GalantamineThe metabolism of Galantamine can be decreased when combined with Levomilnacipran.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levomilnacipran.
GefitinibThe serum concentration of Levomilnacipran can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Levomilnacipran can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Levomilnacipran can be increased when it is combined with Genistein.
GliclazideLevomilnacipran may increase the hypoglycemic activities of Gliclazide.
GlimepirideLevomilnacipran may increase the hypoglycemic activities of Glimepiride.
GlipizideLevomilnacipran may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Levomilnacipran.
GlyburideLevomilnacipran may increase the hypoglycemic activities of Glyburide.
GlyburideThe serum concentration of Levomilnacipran can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Levomilnacipran can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Levomilnacipran can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the serotonergic activities of Levomilnacipran.
GrepafloxacinThe serum concentration of Levomilnacipran can be increased when it is combined with Grepafloxacin.
GuanabenzLevomilnacipran may decrease the antihypertensive activities of Guanabenz.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levomilnacipran.
GuanfacineLevomilnacipran may decrease the antihypertensive activities of Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levomilnacipran.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levomilnacipran.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Levomilnacipran.
HeroinHeroin may increase the serotonergic activities of Levomilnacipran.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levomilnacipran.
HydracarbazineHydracarbazine may increase the serotonergic activities of Levomilnacipran.
HydrochlorothiazideLevomilnacipran may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Levomilnacipran.
HydrocortisoneThe serum concentration of Levomilnacipran can be increased when it is combined with Hydrocortisone.
HydroflumethiazideLevomilnacipran may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Levomilnacipran.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Levomilnacipran.
IdelalisibThe serum concentration of Levomilnacipran can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levomilnacipran.
ImatinibThe metabolism of Levomilnacipran can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levomilnacipran.
IndalpineLevomilnacipran may increase the serotonergic activities of Indalpine.
IndapamideLevomilnacipran may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Levomilnacipran.
IndinavirThe serum concentration of Levomilnacipran can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Levomilnacipran can be increased when it is combined with Indomethacin.
Insulin AspartLevomilnacipran may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirLevomilnacipran may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineLevomilnacipran may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineLevomilnacipran may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanLevomilnacipran may increase the hypoglycemic activities of Insulin Human.
Insulin LisproLevomilnacipran may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Levomilnacipran may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Levomilnacipran.
IproniazidIproniazid may increase the serotonergic activities of Levomilnacipran.
IrbesartanThe metabolism of Levomilnacipran can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Levomilnacipran can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Levomilnacipran.
IsocarboxazidThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levomilnacipran.
IsoniazidThe metabolism of Levomilnacipran can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Levomilnacipran can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Levomilnacipran can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Levomilnacipran can be increased when it is combined with Ivermectin.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomilnacipran.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levomilnacipran.
KetobemidoneKetobemidone may increase the serotonergic activities of Levomilnacipran.
KetoconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Levomilnacipran.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomilnacipran.
LanreotideLevomilnacipran may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Lapatinib.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomilnacipran.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Levomilnacipran.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Levomilnacipran.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Levomilnacipran.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Levomilnacipran.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Levomilnacipran.
LevofloxacinThe serum concentration of Levomilnacipran can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Levomilnacipran.
LevorphanolLevorphanol may increase the serotonergic activities of Levomilnacipran.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Levomilnacipran.
LevothyroxineThe serum concentration of Levomilnacipran can be decreased when it is combined with Levothyroxine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levomilnacipran.
LinezolidLinezolid may increase the serotonergic activities of Levomilnacipran.
LinezolidThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Levomilnacipran.
LiothyronineThe serum concentration of Levomilnacipran can be decreased when it is combined with Liothyronine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Levomilnacipran.
LiotrixThe serum concentration of Levomilnacipran can be decreased when it is combined with Liotrix.
LiraglutideLevomilnacipran may increase the hypoglycemic activities of Liraglutide.
LisinoprilThe serum concentration of Levomilnacipran can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Levomilnacipran.
LofentanilLofentanil may increase the serotonergic activities of Levomilnacipran.
LofexidineLevomilnacipran may decrease the antihypertensive activities of Lofexidine.
LomitapideThe serum concentration of Levomilnacipran can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Levomilnacipran can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Levomilnacipran can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Levomilnacipran.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levomilnacipran.
LorcaserinThe metabolism of Levomilnacipran can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Lorcaserin.
LosartanThe serum concentration of Levomilnacipran can be increased when it is combined with Losartan.
LovastatinThe metabolism of Levomilnacipran can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levomilnacipran.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Levomilnacipran.
Lu AA21004Levomilnacipran may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Levomilnacipran can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Levomilnacipran can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levomilnacipran.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Levomilnacipran.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.
MebanazineMebanazine may increase the serotonergic activities of Levomilnacipran.
MebendazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Mebendazole.
MecaserminLevomilnacipran may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levomilnacipran.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Levomilnacipran.
MefloquineThe serum concentration of Levomilnacipran can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Levomilnacipran can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Levomilnacipran.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Levomilnacipran.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomilnacipran.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomilnacipran.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomilnacipran.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levomilnacipran.
MetforminLevomilnacipran may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Levomilnacipran.
MethadoneMethadone may increase the serotonergic activities of Levomilnacipran.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Levomilnacipran.
MethamphetamineLevomilnacipran may decrease the antihypertensive activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levomilnacipran.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levomilnacipran.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomilnacipran.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Levomilnacipran.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomilnacipran.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.
MethyclothiazideLevomilnacipran may increase the hyponatremic activities of Methyclothiazide.
Methylene blueLevomilnacipran may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomilnacipran.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Levomilnacipran.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.
MetolazoneLevomilnacipran may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Levomilnacipran.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Levomilnacipran.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Levomilnacipran.
MibefradilThe serum concentration of Levomilnacipran can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Miconazole.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levomilnacipran.
MifepristoneLevomilnacipran may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe metabolism of Levomilnacipran can be decreased when combined with Mifepristone.
MiglitolLevomilnacipran may increase the hypoglycemic activities of Miglitol.
MilnacipranMilnacipran may increase the serotonergic activities of Levomilnacipran.
MinaprineMinaprine may increase the serotonergic activities of Levomilnacipran.
MirabegronThe metabolism of Levomilnacipran can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levomilnacipran.
MitomycinThe serum concentration of Levomilnacipran can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Levomilnacipran can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Mitoxantrone.
MoclobemideMoclobemide may increase the serotonergic activities of Levomilnacipran.
MoclobemideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Moclobemide.
ModafinilThe serum concentration of Levomilnacipran can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Levomilnacipran.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Levomilnacipran.
MorphineMorphine may increase the serotonergic activities of Levomilnacipran.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Levomilnacipran.
NadololThe serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.
NafcillinThe serum concentration of Levomilnacipran can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Levomilnacipran.
NaltrexoneThe serum concentration of Levomilnacipran can be increased when it is combined with Naltrexone.
NaphazolineLevomilnacipran may decrease the antihypertensive activities of Naphazoline.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Levomilnacipran.
NaringeninThe serum concentration of Levomilnacipran can be increased when it is combined with Naringenin.
NateglinideLevomilnacipran may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe serum concentration of Levomilnacipran can be decreased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Nefazodone.
NelfinavirThe serum concentration of Levomilnacipran can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Levomilnacipran can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Levomilnacipran can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Levomilnacipran can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Levomilnacipran.
NicardipineThe serum concentration of Levomilnacipran can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Levomilnacipran can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Levomilnacipran can be decreased when combined with Nilotinib.
NisoldipineThe serum concentration of Levomilnacipran can be increased when it is combined with Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levomilnacipran.
NitrendipineThe serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levomilnacipran.
NorepinephrineLevomilnacipran may decrease the antihypertensive activities of Norepinephrine.
NorethisteroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Norethisterone.
NormethadoneNormethadone may increase the serotonergic activities of Levomilnacipran.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levomilnacipran.
OctamoxinOctamoxin may increase the serotonergic activities of Levomilnacipran.
OctreotideLevomilnacipran may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levomilnacipran.
OlaparibThe metabolism of Levomilnacipran can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levomilnacipran.
OmeprazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levomilnacipran.
OpiumOpium may increase the serotonergic activities of Levomilnacipran.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levomilnacipran.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Levomilnacipran.
OsimertinibThe serum concentration of Levomilnacipran can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levomilnacipran.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Levomilnacipran.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levomilnacipran.
OxycodoneOxycodone may increase the serotonergic activities of Levomilnacipran.
OxymetazolineLevomilnacipran may decrease the antihypertensive activities of Oxymetazoline.
OxymorphoneOxymorphone may increase the serotonergic activities of Levomilnacipran.
P-NitrophenolThe serum concentration of Levomilnacipran can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Levomilnacipran can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Levomilnacipran can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levomilnacipran.
Palmitic AcidThe serum concentration of Levomilnacipran can be increased when it is combined with Palmitic Acid.
PalonosetronPalonosetron may increase the serotonergic activities of Levomilnacipran.
PanobinostatThe metabolism of Levomilnacipran can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Pantoprazole.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Levomilnacipran.
PargylinePargyline may increase the serotonergic activities of Levomilnacipran.
ParoxetineLevomilnacipran may increase the serotonergic activities of Paroxetine.
ParoxetineThe serum concentration of Levomilnacipran can be increased when it is combined with Paroxetine.
PasireotideLevomilnacipran may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Levomilnacipran can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Levomilnacipran.
PentamidineLevomilnacipran may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Levomilnacipran.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levomilnacipran.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Levomilnacipran.
PergolideLevomilnacipran may decrease the antihypertensive activities of Pergolide.
PerindoprilThe serum concentration of Levomilnacipran can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Levomilnacipran.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levomilnacipran.
PethidinePethidine may increase the serotonergic activities of Levomilnacipran.
PethidineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Levomilnacipran.
PhenelzineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Phenelzine.
PhenindioneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Levomilnacipran.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levomilnacipran.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Levomilnacipran.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Levomilnacipran.
PhenprocoumonThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Phenprocoumon.
PhenylpropanolamineLevomilnacipran may decrease the antihypertensive activities of Phenylpropanolamine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levomilnacipran.
PimozideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Levomilnacipran.
PioglitazoneLevomilnacipran may increase the hypoglycemic activities of Pioglitazone.
PioglitazoneThe metabolism of Levomilnacipran can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levomilnacipran.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levomilnacipran.
PirlindolePirlindole may increase the serotonergic activities of Levomilnacipran.
PivhydrazinePivhydrazine may increase the serotonergic activities of Levomilnacipran.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Levomilnacipran.
Platelet Activating FactorThe serum concentration of Levomilnacipran can be decreased when it is combined with Platelet Activating Factor.
PolythiazideLevomilnacipran may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.
PonatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Levomilnacipran.
PramlintideLevomilnacipran may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levomilnacipran.
PravastatinThe serum concentration of Levomilnacipran can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran.
PrazosinThe serum concentration of Levomilnacipran can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Levomilnacipran can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levomilnacipran.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levomilnacipran.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Levomilnacipran.
ProbenecidThe serum concentration of Levomilnacipran can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levomilnacipran.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Levomilnacipran.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.
ProgesteroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Levomilnacipran.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levomilnacipran.
PropafenoneThe serum concentration of Levomilnacipran can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomilnacipran.
PropericiazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levomilnacipran.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Levomilnacipran.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Levomilnacipran.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Levomilnacipran.
PseudoephedrineLevomilnacipran may decrease the antihypertensive activities of Pseudoephedrine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levomilnacipran.
QuercetinThe serum concentration of Levomilnacipran can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomilnacipran.
QuinacrineThe serum concentration of Levomilnacipran can be increased when it is combined with Quinacrine.
QuinethazoneLevomilnacipran may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Levomilnacipran can be increased when it is combined with Quinidine.
QuinineLevomilnacipran may increase the hypoglycemic activities of Quinine.
QuinineThe serum concentration of Levomilnacipran can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Levomilnacipran can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levomilnacipran.
RanitidineThe serum concentration of Levomilnacipran can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Levomilnacipran can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Levomilnacipran.
RasagilineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Rasagiline.
ReboxetineThe serum concentration of Levomilnacipran can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Levomilnacipran can be increased when it is combined with Regorafenib.
RemifentanilRemifentanil may increase the serotonergic activities of Levomilnacipran.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levomilnacipran.
RepaglinideLevomilnacipran may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levomilnacipran.
RifabutinThe metabolism of Levomilnacipran can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Levomilnacipran can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Levomilnacipran can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Levomilnacipran can be increased when it is combined with Rilpivirine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Levomilnacipran.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levomilnacipran.
RitonavirThe serum concentration of Levomilnacipran can be decreased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Levomilnacipran.
RolapitantThe serum concentration of Levomilnacipran can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Levomilnacipran.
RopiniroleThe metabolism of Levomilnacipran can be decreased when combined with Ropinirole.
RopiniroleLevomilnacipran may decrease the antihypertensive activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomilnacipran.
RosiglitazoneLevomilnacipran may increase the hypoglycemic activities of Rosiglitazone.
RosiglitazoneThe metabolism of Levomilnacipran can be decreased when combined with Rosiglitazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levomilnacipran.
SafrazineSafrazine may increase the serotonergic activities of Levomilnacipran.
SaquinavirThe serum concentration of Levomilnacipran can be decreased when it is combined with Saquinavir.
SaxagliptinLevomilnacipran may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levomilnacipran.
SelegilineSelegiline may increase the serotonergic activities of Levomilnacipran.
SelegilineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Levomilnacipran.
SertralineLevomilnacipran may increase the serotonergic activities of Sertraline.
SertralineThe serum concentration of Levomilnacipran can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levomilnacipran.
SildenafilThe metabolism of Levomilnacipran can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Levomilnacipran can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Levomilnacipran can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Levomilnacipran can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Levomilnacipran can be decreased when it is combined with Sirolimus.
SitagliptinLevomilnacipran may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Levomilnacipran.
SorafenibThe serum concentration of Levomilnacipran can be increased when it is combined with Sorafenib.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Levomilnacipran.
SpironolactoneThe serum concentration of Levomilnacipran can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Levomilnacipran can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Levomilnacipran can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Levomilnacipran.
StreptozocinThe serum concentration of Levomilnacipran can be decreased when it is combined with Streptozocin.
SufentanilSufentanil may increase the serotonergic activities of Levomilnacipran.
SulfadiazineLevomilnacipran may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleLevomilnacipran may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleThe metabolism of Levomilnacipran can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Levomilnacipran can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleLevomilnacipran may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Levomilnacipran can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomilnacipran.
SumatriptanThe serum concentration of Levomilnacipran can be increased when it is combined with Sumatriptan.
SumatriptanThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sumatriptan.
SunitinibLevomilnacipran may increase the hypoglycemic activities of Sunitinib.
SunitinibThe serum concentration of Levomilnacipran can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Levomilnacipran.
TacrineThe serum concentration of Levomilnacipran can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Levomilnacipran.
TacrolimusThe serum concentration of Levomilnacipran can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Levomilnacipran can be decreased when it is combined with Tamoxifen.
TapentadolTapentadol may increase the serotonergic activities of Levomilnacipran.
TapentadolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Levomilnacipran.
Taurocholic AcidThe serum concentration of Levomilnacipran can be increased when it is combined with Taurocholic Acid.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Levomilnacipran.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Levomilnacipran can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Levomilnacipran can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Levomilnacipran can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomilnacipran.
TemsirolimusThe serum concentration of Levomilnacipran can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Levomilnacipran can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Levomilnacipran can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Levomilnacipran can be increased when it is combined with Terfenadine.
TeriflunomideThe metabolism of Levomilnacipran can be decreased when combined with Teriflunomide.
TesmilifeneThe serum concentration of Levomilnacipran can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Levomilnacipran can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levomilnacipran.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levomilnacipran.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levomilnacipran.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levomilnacipran.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomilnacipran.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Levomilnacipran.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomilnacipran.
ThioproperazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levomilnacipran.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levomilnacipran.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Levomilnacipran.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levomilnacipran.
TicagrelorThe serum concentration of Levomilnacipran can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Levomilnacipran can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Levomilnacipran.
TimololThe serum concentration of Timolol can be increased when it is combined with Levomilnacipran.
TipranavirThe metabolism of Levomilnacipran can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levomilnacipran.
TizanidineLevomilnacipran may decrease the antihypertensive activities of Tizanidine.
TocilizumabThe serum concentration of Levomilnacipran can be decreased when it is combined with Tocilizumab.
TolazamideLevomilnacipran may increase the hypoglycemic activities of Tolazamide.
TolbutamideLevomilnacipran may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levomilnacipran.
ToloxatoneToloxatone may increase the serotonergic activities of Levomilnacipran.
TolvaptanThe serum concentration of Levomilnacipran can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Levomilnacipran.
TramadolLevomilnacipran may increase the neuroexcitatory activities of Tramadol.
TramadolTramadol may increase the serotonergic activities of Levomilnacipran.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Levomilnacipran.
TranylcypromineTranylcypromine may increase the serotonergic activities of Levomilnacipran.
TranylcypromineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomilnacipran.
TrazodoneLevomilnacipran may increase the serotonergic activities of Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomilnacipran.
TrichlormethiazideLevomilnacipran may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomilnacipran.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levomilnacipran.
TrimethoprimThe serum concentration of Levomilnacipran can be decreased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levomilnacipran.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levomilnacipran.
TroleandomycinThe serum concentration of Levomilnacipran can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levomilnacipran.
VenlafaxineThe metabolism of Levomilnacipran can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Venlafaxine.
VerapamilThe metabolism of Levomilnacipran can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Levomilnacipran.
VilazodoneVilazodone may increase the serotonergic activities of Levomilnacipran.
VinblastineThe serum concentration of Levomilnacipran can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Levomilnacipran can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Levomilnacipran can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Levomilnacipran can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levomilnacipran.
VortioxetineLevomilnacipran may increase the serotonergic activities of Vortioxetine.
WarfarinThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Levomilnacipran.
XylometazolineLevomilnacipran may decrease the antihypertensive activities of Xylometazoline.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomilnacipran.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levomilnacipran.
ZimelidineLevomilnacipran may increase the serotonergic activities of Zimelidine.
ZimelidineThe serum concentration of Levomilnacipran can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levomilnacipran.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Levomilnacipran.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Levomilnacipran.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levomilnacipran.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levomilnacipran.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levomilnacipran.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Levomilnacipran.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levomilnacipran.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on August 01, 2013 14:17 / Updated on September 24, 2016 02:17